Without the right patent strategy, drug developers risk losing investors and sacrificing commercial potential.

On this weeks episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...

On this weeks episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s.

Five of the best-known contract sales providers have changed owners, leaders, or reporting structure since 2022. Contracts should reflect those changes, writes Hoyt Gong.

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

IN 2017, SAQIB ISLAM FOUND HIMSELF FACING ONE OF THOSE PIVOTAL CAREER DECISIONS — LEAVE A GOOD JOB AT A GOOD COMPANY FOR THE CHANCE TO GROW A FLEDGLING STARTUP. He was only a year into his job as ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

Drug and device manufacturers have long sought clearer rules for sharing scientific information about unapproved (off-label) uses of their products with health care providers (“HCPs”). In January 2025 ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...